takeaway wuxi investor day
wuxi biolog wuxi first time gather full senior manag
team manufactur site wuxi citi share vision
compani strategi oper
manag present posit view biolog industri
wuxi uniqu competit advantag futur growth
futur growth
investor analyst attend wuxi investor day
investor major concern still focus futur growth driver
compani well impact us-china trade war manag re-
emphasis new initi vaccin bi-specif antibodi
would becom new growth engin next three five year
less wuxi current revenu could subject potenti us tariff
manag provid guidanc investor day said
target new project per year exist project could
deliv growth year upon move late stage gener
mileston royalti revenu project total current
phase manag said expect two three
project transit commerci stage year servic mileston
backlog continu grow steadili year
manag highlight key catalyst oper side
includ ema gmp certif obtain facil
 on-line conjug vial on-line
first bioreactor product first ind wuxibodi
wuxiup product one three bla file
maintain outperform tp tp base
dcf model assum wacc perpetu growth rate
downsid risk rate tp includ less-than-expect growth
late-stag project less success rate propitiatori platform
valuat metric
chg prev ep
number share mn
price month
price rel chart measur perform
china close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
figur key mileston catalyst
vial facil
bioreactor
ind
ind
wuxi biolog global lead biolog servic provid
offer comprehens integr highli customiz servic
drug discoveri develop manufactur biolog
good sold
profit tax
free cash flow firm
net chang cash
blue sky valuat hk assum number new
project enrol higher central case
ebitda margin mid-long term
grey sky valuat assum number new
project enrol lower central case
ebitda margin mid-long term
price rel chart measur perform china
close
spot exchang rate
note wuxi investor day
cqo dr chiang syin
first time wuxi gather entir senior manag team share
vision compani investor dr chri chen gave overview wuxi
follow detail introduct busi unit senior manag
overview wuxi dr chri chen
dr chri chen start industri overview highlight four driver
support quick growth global biolog outsourc market includ
increas spend cost
time save suppli chain capac
manag leverag outsid technolog result global biolog
outsourc market share could increas
view boom industri wuxi player provid full spectrum
explain detail wuxi uniqu busi model follow molecul
key featur model client molecul advanc develop
stage demand wuxi servic would increas result big revenu
increas project typic servic revenu annual discoveri pre-
clinic phase phase commercial-stag project mn
mn mn mn mn
respect project pre-clin stage
phase phase one commerci stage besid servic
revenu wuxi also receiv mileston royalti fee certain project
mileston fee mn typic global programm mn
chines programm royalti start typic go annual
product sale year
dr chri chen explain maintain steadi growth backlog new add-on
project critic portion backlog previou year turn
actual revenu taken backlog new project
ad backlog jump bn year bn
anoth import featur wuxi busi model global dual sourc
allow wuxi partner select two manufactur site within wuxi better
manufactur manag de-risk amicu use model chose
wuxi exclus manufactur partner
wuxi client base becom diversifi revenu share top
top client declin
respect make wuxi busi stabl term revenu wuxi account
global market term number project wuxi
global share gap due uniqu busi model wherebi wuxi
engag client even product still earli stage initi
revenu project big grow fast project matur
dr chri chen highlight key competit advantag wuxi enabl
continu gain market share includ cutting-edg technolog wuxibodi
wuxia cell line wuxiup best timelin three six month less industri
averag good track record deliveri unlimit capac project
start within four week also point recent wuxi vaccin deal
biggest breakthrough compani histori far vaccin manufactur
difficult vaccin life-cycl longer biolog greater client
sticki project could gener revenu reach mn
total revenu contract exce bn
point us-china trade tension limit impact wuxi
busi less revenu could subject potenti us tariff china tariff
us equip raw materi could reduc profit mn
absorb wuxi
final highlight key catalyst includ ema gmp certif obtain
facil on-line on-line first
bioreactor product first ind wuxibodi wuxiup product
one three bla file
introduct financi result cfo christin lu-wong
point three import key number besid financi indic
understand wuxi perform overal integr project number
new project number late-phas project number
perform paramet backlog capac employe
number correl three key number financi result
could deriv
introduct biolog discoveri cso dr jiji gu
dr jiji gu join wuxi recent come year experi biolog
 discoveri team scientist includ phd md
mss
gener drug screen exploratori preclin develop multipl
phase display librari
dr jiji gu emphasis bispecif antibodi bsab programm wuxi
three format gener bsab wuxi includ gener bispecif format
wuxibsab common light chain-bas format omnifl wuxi proprietari
bispecif format wuxibodi highlight key advantag wuxibodi
univers platform antibodi pair flexibl gener bi/tri/tetra-val
bsab save month develop time gener bsab expect
low immunogen
dr jiji gu explain workflow antibodi drug develop start
uniqu biolog discoveri follow match optim format select
right drug molecul point wuxi use two screen funnel function
properti screen funnel develop funnel parallel select optim
drug candid better success rate develop
introduct biolog develop dr weichang zhou
dr weichang zhou point wuxi largest biolog develop organis
among cdmo capac ind bla year promis start
everi project within four week sign contract
develop team strength april includ oversea
returne current project cover format includ monoclon
antibodi fusion protein adc bsab other enzym
project first-in-class
biolog develop effici improv everi year acceler
timelin dna ind reduc month
month use wuxi wuxia cho cell line platform yellow fever mab
project achiev record timelin month dna ind
dr weichang zhou emphasis wuxi proprietari continu manufactur
platform wuxiup compani obtain fda endors would
includ ich guidelin june wuxiup platform enabl continu
cell cultur direct product captur achiev yield
day continu cell cultur process fc-fusion protein project order
high yield could densiti mn cells/ml viabil
enabl increas yield lower cost compar tradit singl
lastli dr zhou said forese growth beyond come adc microbi
technolog platform live viru product platform wuxi new district
dedic adc kg/batch batch per year capac
introduct facil global bio-manufactur head jian dong
wuxi total bioreactor capac global suppli chain
network across china ireland us singapor wuxi site account
capac receiv gmp audit global client pass
us fda pre-licensur inspect ema inspect emphasis wuxi
global leader dispos bioreactor technolog less invest
batch product compar convent feb-batch bioreactor
also point wuxi facil first robot asept fill line vanrx
china elimin human interfer relat qualiti risk
introduct qualiti control system cqo dr chiang syin
ensur high qualiti control wuxi continu build qualiti cultur
emphasis person ownership data qualiti extens train
programm also turn everi staff member master method instrument
meet globalis need wuxi centralis qualiti system maintain
intern practic procedur among site enhanc data
align
autom procedur control well enforc
complianc client intern audit
attract retain best employe control labour cost
wuxi provid best studi develop platform employe
wuxi employe achiev shorter time-frame tackl
challeng project therefor turnov rate key employe addit
wuxi becom matur platform run smoothli even key
sourc wuxi futur growth consid market share
alreadi high term molecul number
follow molecul strategi mean even new project ad wuxi
revenu could still enjoy decent growth exist project move later stage
mileston royalti fee also provid substanti revenu growth addit
wuxi exist project monoclon antibodi move forward bsab
vaccin project becom revenu growth engin
concern run new biolog target futur
new biolog target emerg everi year worri
run new target current biolog target concentr oncolog
autoimmun diseas move forward infect diseas target could becom
common even exist target bsab gener new valuabl drug
domest capac much
expans correl increas project need therefor oversuppli
capac doesnt affect wuxi busi wuxi cutting-edg technolog rich
experi also enhanc client loyalti wuxi
wuxi back-up plan cultur medium bioreactor suppli
wuxi platform current project use exist
technolog project mani uncertainti medium
bioreactor wuxi multipl suppli chain mani eu move
forward wuxi invest upstream biotech compani secur suppli
continuous-manufactur platform matur
wuxi use continuous-manufactur seven year previous use
protein project recent expand kind biolog includ
price typic bsab project
higher monoclon antibodi project overal valu typic baab
project mn royalti fee proof concept wuxibodi platform
clinic data bsab price might increas
sinc mani biotech compani build manufactur facil
wuxi win maintain busi
build facil doesnt mean effici run success gener
product eventu wuxi might win/maintain busi biotech
wuxi oversea facil higher cost domest one
ye margin ireland us facil could less domest
consid us-china trade war wuxi switch upstream supplier
bioreactor exampl us eu
plan moment
wuxi new technolog develop plan
mani new plan disclos due uncertainti
certain develop would stabl high-yield manufactur g/l
mani overlap target newli imit project
overlap sever wuxi initi project novel
target academ professor
discoveri busi revenu profit contribut
wuxi doesnt disclos number term project number discoveri account
hope number reach futur
hard-cor technolog wuxi discoveri busi
biolog discoveri platform good screen platform good protein-
engin platform key advantag wuxi discoveri busi
global biolog maintain current high level small-molecul
drug catch
biolog account spend bm roch sanofi
trend might continu small molecul becom challeng
potenti slowdown global economi due trade-war effect
wuxi middle- small-siz client
wuxi client ask trade-war relat question us biotech might
face valuat correct pressur china biotech still boom even
market downturn wuxi could gain market share
compani mention price
